Table 4.

Relation between DEL and DHL

Outcome	BCL2/c-Myc Expression				p-value	Double hit		p-value
	Non-expressor (N=43)	BCL2 expressor (N=15)	c-Myc expressor (N=5)	Double expressor (N=27)		Absent (N=83)	Present (N=7)
	No. (%)	No. (%)	No. (%)	No.(%)		No. (%)	No. (%)
Response
PD	0 (0.0%)	4 (26.7%)	3 (60%)	20 (74.1%)	<0.001¦	20 (24.1%)	7 (100%)	0.001‡
SD	2 (4.6%)	6 (40.0%)	1 (20%)	6 (22.2%)		15 (18.1%)	0 (0%)
PR	23 (53.5%)	3 (20.0%)	1 (20%)	1 (3.7%)		28 (33.7%)	0 (0%)
CR	18 (41.9%)	2 (13.3%)	0 (0%)	0 (0%)		20 (24.1%)	0 (0%)
NR	2 (4.7%)	10 (66.7%)	4 (80%)	26 (96.3%)	<0.001¦	35 (42.2%)	7 (100%)	0.004‡
OAR	41 (95.3%)	5 (33.3%)	1 (20%)	1 (3.7%)		48 (57.8%)	0 (0%)
Relapse	(N=18)	(N=2)				(N=20)
Before 24 month	8 (44.4%)	0 (0%)			0.495‡	8 (40%)		---
After 24 month	10 (55.6%)	2 (100%)				12 (60%)
RFS
Mean RFS	24.33 month	28 month			0.416†	24.70 month
(95%CI)	(22.34-26.33)	(24.08-31.92)				(22.82-26.58)
Median RFS	25 month	26 month				25 month
24 month RFS	55.6%	100%				60%
30 month RFS	5.6%	0%				5%
Progression	(N=25)	(N=8)	(N=2)	(N=7)
Within 6month	13 (52%)	8 (100%)	2 (100%)	7 (100%)	0.005¦
After 6 month	12 (48%)	0 (0%(	0 (0%)	0 (0%)
PFS
Mean PFS	6.60 months	3.38 months	3.50 months	1.57 months	<0.001†
(95%CI)	(5.91-7.29)	(3.02-3.373)	(2.52-4.48)	(1.18-1.97)
Median PFS	6 months	3 months	3 months	2 months
3 month PFS	100%	37.5%	50%	0%
6 month PFS	48%	0%	0%	0%
9 month PFS	8%	0%	0%	0%
Mortality
Alive	43 (100%)	13 (86.7%)	3 (60%)	7 (25.9%)	<0.001¦	66 (79.5%)	0 (0%)	<0.001‡
Died	0 (0%)	2 (13.3%)	2 (40%)	20 (74.1%)		17 (20.5%)	7 (-100%)
OS
Mean OS	36 month	30.64 month	26.40 month	14.95 month	<0.001†	31.57 month	6.57 month	<0.001†
(95%CI)		(27.54-33.75)	(17.41-35.39)	(11.93-17.96)		(29.68-33.46)	(4.98-8.16)
Median OS		NR	35 month	14 month		36 month	6 month
24 month OS	100%	85.7%	53.3%	12.4%		78.9%	0%
30 month OS	100%	85.7%	53.3%	12.4%		78.9%	0%

Double expressor/double hit lymphomas*